Table 1.

Patient characteristics.

Characteristics	Total [n=73]a	Responderd [n=46]a	Non-responder [n=27]a	p Valuec
Age at MTX initiation [years]d	30 [14-67]	28 [14-65]	35 [15-52]	0.57
Median duration of disease at MTX initiation [years]d	5 [0-43]	5 [0-32]	5 [2-43]	0.93
Median duration of MTX use [months]d	17 [0-112]	17 [2-112]	6 [0-18]	0.91
Male sex	50 [69%]	34 [74%]	16 [59%]	0.30
Smokers, former smokers	7 [10%], 9 [12%]	6 [13%], 5 [11%]	1 [46%], 4 [15%]	0.25; 0.72
Crohn’s disease	54 [74%]	35 [76%]	19 [70%]	0.79
Age at diagnosis [years] [A1, A2, A3]e	18 [33%], 31 [57%] 5 [9%]	12 [34%], 20 [57%], 3 [9%]	6 [32%], 11 [58%], 2 [11%]	0.78; 0.82; 1.00
Location [L1, L2, L3]f	10 [18%], 8 [15%], 36 [67%]	7 [20%], 3 [9%], 25 [71%]	3 [16%], 5 [26%], 11 [58%]	0.74; 0.14; 0.38
Addition of L4f	11 [20%]	7 [20%]	4 [21%]	1.00
Crohn’s disease
Behavior [B1, B2, B3]g	18 [33%], 15 [28%] 21 [39%]	12 [34%], 9 [36%] 14 [40%]	6 [32%], 6 [32%] 7 [37%]	0.93; 0.79; 0.89
Perianal disease	19 [35%]	13 [37%]	6 [32%]	0.77
Ulcerative colitis	16 [22%]	8 [17%]	8 [30%]	0.36
Extent
- Left-sided	6 [38%]	3 [38%]	3 [38%]	0.66
- Extensive	10 [62%]	5 [63%]	5 [63%]	0.57
Indeterminate colitis	3 [4%]	3 [7%]	0	0.29
Low-dose MTXh	51 [71%]	32 [70%]	19 [70%]	0.94
Oral MTX route	55 [75%]	35 [76%]	20 [74%]	0.85
Concomitant anti-TNF agent
- Adalimumab	36 [49%]	24 [52%]	12 [44%]	0.56
- Infliximab	29 [40%]	20 [43%]	9 [33%]	0.54
- Certolizumab pegol	8 [11%]	2 [4%]	6 [22%]	0.05

MTX, methotrexate; anti-TNF, anti tumor necrosis factor.

^a% relates to the total n per column.

^bResponder, achieved remission after induction of MTX therapy.

^cLow dose equals ≤ 12.5 mg.

^dAge and duration are expressed as median [range].

^eA1 <16 years; A2 17-49 years; A3 >40 years.

^fL1 ileal; L2 colonic; L3 ileocolonic; L4 upper GI.

^gB1 non-stricturing, non-penetrating; B2 stricturing; B3 penetrating.

^hCalculated for responders versus non-responders.